L Rimsky

3.8k citations

39 papers · 3.2k indexed · h-index 25

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 22
- HIV Research and Treatment 22
Infectious Diseases 24
- HIV/AIDS drug development and treatment 23
- HIV/AIDS Research and Interventions 15

Co-authors: Thomas J. Matthews Katia Boven Diane C. Shugars Simon Vanveggel Gastón Picchio Warner C. Greene Herta Crauwels Johan Vingerhoets
Journals: Antiviral Therapy (4 papers)Journal of Virology (4 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (3 papers)Journal of the International AIDS Society (3 papers)Antimicrobial Agents and Chemotherapy (3 papers)
Partner nations: United States France Belgium

In The Last Decade

L Rimsky

38 papers receiving 3.0k citations

Peers

Countries citing papers authored by L Rimsky

Since Specialization

Citations

This map shows the geographic impact of L Rimsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Rimsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Rimsky more than expected).

Fields of papers citing papers by L Rimsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Rimsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Rimsky. The network helps show where L Rimsky may publish in the future.

Co-authors

The 25 scholars most cited alongside L Rimsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with L Rimsky Line = papers co-authored together L Rimsky links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis AIDS Patient Care and STDs ·Georg M. N. Behrens, Bart Rijnders, Mark Nelson, Chloe Orkin, Calvin Cohen, Anthony Mills, Richard Elion, Simon Vanveggel, Marita Stevens, L Rimsky, David Thorpe, Veronika Danek, Kirsten White, Lijie Zhong, Sushma Kumari Singh, Susan K. Chuck	2014	23
2	Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less AIDS ·Jean‐Michel Molina, Nathan Clumeck, I. Codony, L Rimsky, Simon Vanveggel, Marita Stevens	2013	22
3	96-Week Resistance Analyses of Rilpivirine in Treatment-Naive, HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials Antiviral Therapy ·L Rimsky, Veerle Van Eygen, Annemie Hoogstoel, Marita Stevens, Katia Boven, Gastón Picchio, Johan Vingerhoets	2013	35
4	Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response Antiviral Therapy ·Johan Vingerhoets, L Rimsky, Veerle Van Eygen, Steven Nijs, Simon Vanveggel, Katia Boven, Gastón Picchio	2012	31
5	Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials AIDS ·Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank S. Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven	2012	103
6	Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial AIDS Research and Human Retroviruses ·Aimee Wilkin, Anton Pozniak, Javier O Morales-Ramirez, Sergio Lupo, Sibel YILDIZ KISACIK, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, 小山裕樹	2011	45
7	The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness JAIDS Journal of Acquired Immune Deficiency Syndromes ·Rima Kulkarni, Kerim Babaoglu, E.B. Lansdon, L Rimsky, Veerle Van Eygen, Gastón Picchio, Evguenia S. Svarovskaia, Michael D. Miller, Kirsten White	2011	69
8	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial The Lancet ·Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet, Jan Fourie, Margaret Johnson, Kiat Ruxrungtham, Hao Wu, Carmen Zorrilla, Herta Crauwels, L Rimsky, Simon Vanveggel, Katia Boven	2011	286
9	Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults Calvin Cohen, Zou Tianyi, Jean‐Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Frank S. Rhame, 段金林, E. Bresciani, Herta Crauwels, L Rimsky, Simon Vanveggel, Paulette Williams, Katia Boven, Оксана М. Пильтяй	2011	13
10	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial The Lancet ·Jean‐Michel Molina, Pedro Cahn, Beatriz Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael S. Saag, Khuanchai Supparatpinyo, Sharon Walmsley, Herta Crauwels, L Rimsky, Simon Vanveggel, Katia Boven	2011	315
11	Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies JAIDS Journal of Acquired Immune Deficiency Syndromes ·L Rimsky, Johan Vingerhoets, Veerle Van Eygen, Joseph J. Eron, Bonaventura Clotet, Annemie Hoogstoel, Katia Boven, Gastón Picchio	2011	133
12	Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data AIDS Research and Human Retroviruses ·Johan Vingerhoets, Hilde Azijn, Lotke Tambuyzer, Inge Dierynck, Sandra De Meyer, L Rimsky, Steven Nijs, Goedele De Smedt, Marie‐Pierre de Béthune, Gastón Picchio	2010	11
13	Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial AIDS ·Anton Pozniak, Javier O Morales-Ramirez, Elly Katabira, Dewald Steyn, Sergio Lupo, Sibel YILDIZ KISACIK, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, Katia Boven	2009	89
14	Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine Nucleosides Nucleotides & Nucleic Acids ·Joy Y. Feng, Florence Myrick, Nicolas Margot, Kelly Enomoto, L Rimsky, Katyna Borroto–Esoda, Boulbaba Selmi, Bruno Canard	2006	20
15	Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides Journal of Virology ·L Rimsky, Diane C. Shugars, Thomas J. Matthews	1998	376
16	Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator Nature ·L Rimsky, Yan En-ping, Eric P. Dixon, Warner C. Greene	1989	67
17	Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein Nature ·L Rimsky, Joachim Hauber, Mitchell Dukovich, Michael H. Malim, A J Langlois, Bryan R. Cullen, Warner C. Greene	1988	183
18	Cloning and expression of a cDNA for human thioredoxin. Journal of Biological Chemistry ·E Wollman, L d'Auriol, L Rimsky, Alan Shaw, Jean‐Pierre Jacquot, Paul T. Wingfield, Pierre Graber, Phil Drummond, Philippe Robin, Francis Galibert	1988	211
19	B-cell-derived interleukin-1 Annales de l Institut Pasteur Immunologie ·Hiro Wakasugi, عبد القادر عوادي, Yann F. Mahé, Pierre Busson, L Rimsky, D Fradelizi, Jacques Bertoglio, Thomas Tursz	1987	2
20	In vitro immune response to sheep erythrocytes in macrophage depleted cultures. Restoration with interleukine 1 or a monokine from resident macrophages and stimulation by N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) Biochemical and Biophysical Research Communications ·Vongthip Souvannavong, L Rimsky, Arlette Adam	1983	11

About L Rimsky

L Rimsky is a scholar working on Virology, Infectious Diseases, Immunology, Agronomy and Crop Science and Ecology, Evolution, Behavior and Systematics, having authored 39 papers that have together received 3.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (22 papers), HIV/AIDS Research and Interventions (15 papers), T-cell and Retrovirus Studies (5 papers), Animal Disease Management and Epidemiology (5 papers), Vector-Borne Animal Diseases (5 papers), Immune Cell Function and Interaction (4 papers) and Herpesvirus Infections and Treatments (3 papers). The work is most often cited by research in Virology (1.9k citations), Infectious Diseases (2.0k citations), Agronomy and Crop Science (332 citations), Immunology (655 citations) and Hepatology (189 citations). L Rimsky has collaborated with scholars based in United States, France and Belgium. Frequent co-authors include Thomas J. Matthews, Katia Boven, Diane C. Shugars, Simon Vanveggel, Gastón Picchio, Warner C. Greene, Herta Crauwels, Johan Vingerhoets, Bonaventura Clotet and Beatriz Grinsztejn. Their work appears in journals such as Antiviral Therapy, Journal of Virology, JAIDS Journal of Acquired Immune Deficiency Syndromes, Journal of the International AIDS Society and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact